Praxis Precision Medicines Inc. (PRAX): Price and Financial Metrics

Praxis Precision Medicines Inc. (PRAX): $53.39

1.77 (-3.21%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add PRAX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#153 of 363

in industry

PRAX Price/Volume Stats

Current price $53.39 52-week high $67.21
Prev. close $55.16 52-week low $12.45
Day low $52.72 Volume 109,800
Day high $55.04 Avg. volume 215,281
50-day MA $50.35 Dividend yield N/A
200-day MA $28.42 Market Cap 706.78M

PRAX Stock Price Chart Interactive Chart >


Praxis Precision Medicines Inc. (PRAX) Company Bio


Praxis Precision Medicines, Inc. is a clinical-stage genetic neuroscience company that develops therapies for patients and families affected by complex and debilitating brain disorders. The company was founded by Kiran Reddy, David Goldstein and Steven Petrou on September 22, 2015 and is headquartered in Cambridge, MA.


PRAX Latest News Stream


Event/Time News Detail
Loading, please wait...

PRAX Latest Social Stream


Loading social stream, please wait...

View Full PRAX Social Stream

Latest PRAX News From Around the Web

Below are the latest news stories about PRAXIS PRECISION MEDICINES INC that investors may wish to consider to help them evaluate PRAX as an investment opportunity.

Wall Street Analysts Believe Praxis Precision Medicines, Inc. (PRAX) Could Rally 494.95%: Here's is How to Trade

The mean of analysts' price targets for Praxis Precision Medicines, Inc. (PRAX) points to a 495% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 30, 2023

Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings

BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its epilepsy programs at the following upcoming meetings in Orlando, Florida. Presentations at the American Epilepsy Society (AES) Annual Meeting,

Yahoo | November 28, 2023

Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | November 24, 2023

Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference

BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside discussion at the Piper Sandler Healthcare Conference on November 28, 2023 at 10:00am. The event will be available via live webcast throug

Yahoo | November 21, 2023

Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies

BOSTON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that the European Medical Agency (EMA) has awarded its Priority Medicines (PRIME) designation for elsunersen (PRAX-222) for the treatment of SCN2A Gain of Function (GoF) developmental a

Yahoo | November 16, 2023

Read More 'PRAX' Stories Here

PRAX Price Returns

1-mo -3.17%
3-mo 29.74%
6-mo 184.75%
1-year 255.93%
3-year -87.00%
5-year N/A
YTD 139.63%
2023 -37.59%
2022 -87.92%
2021 -64.19%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!